Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study

Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study

Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation. There are few data on the efficacy and safety in clinical practice of infliximab (CT-P13) in subcutaneous formulation (SC) for the treatment...

Full description

Bibliographic Details
Main Authors: Jose M. Huguet, Victor García-Lorenzo, Lidia Martí, Jose María Paredes, Jose Joaquin Ramírez, Miguel Pastor, Lucia Ruiz, Ana Sanahuja, Pilar Timoneda, Laura Sanchís, Gloria Alemany Pérez, Marta Maia Boscá-Watts
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Biomedicines
Subjects:
infliximab
CT-P13
infliximab trough level
inflammatory bowel disease
Crohn’s disease
ulcerative colitis
Online Access:https://www.mdpi.com/2227-9059/10/9/2130

Internet

https://www.mdpi.com/2227-9059/10/9/2130

Similar Items